🇺🇸 FDA
Patent

US 10869851

Targeting NUR77 for mitigating perinatal neuroinflammation

granted A61KA61K31/216A61K31/57

Quick answer

US patent 10869851 (Targeting NUR77 for mitigating perinatal neuroinflammation) held by United States Government as represented by the Secretary of the Army expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Secretary of the Army
Grant date
Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/216, A61K31/57, A61K31/573, A61K45/06